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Abstract
Background: Chronic kidney disease (CKD) risk is elevated in 
patients with type 2 diabetes mellitus (T2DM). Disease man-
agement in these patients has been generally focused on 
glycemic control and controlling other renal and cardiac 
risk factors as, historically, few protective therapies have 
been available. The Canagliflozin and Renal Events in Diabe-
tes with Established Nephropathy Clinical Evaluation 
 (CREDENCE) trial of canagliflozin was the first study to dem-
onstrate renal protection with a sodium glucose co-trans-
porter 2 inhibitor in patients with T2DM and CKD, and these 
results could have important implications for clinical prac-
tice. Summary: In CREDENCE, participants with T2DM and 
estimated glomerular filtration rate 30–< 90 mL/min/1.73 m2 
and urinary albumin-creatinine ratio > 300–5,000 mg/g who 
were treated with an angiotensin-converting enzyme inhib-
itor or angiotensin receptor blocker for ≥4 weeks prior to 
randomization at either the maximum labeled or tolerated 
dose were randomized to receive either canagliflozin 100 mg 
or placebo. Canagliflozin significantly reduced the risk of the 
primary composite outcome of doubling of serum creati-
nine, end-stage kidney disease, or renal or cardiovascular 
(CV) death compared with placebo (hazard ratio 0.70, 95% CI 
0.59–0.82; p = 0.00001). Canagliflozin also reduced the risk of 
secondary renal and CV outcomes. The safety profile of cana-
gliflozin in CREDENCE was generally similar to previous stud-
ies of canagliflozin. No imbalances were observed between
canagliflozin and placebo in the risk of amputation or frac-
ture in the CREDENCE population. Key Messages: The posi-
tive renal and CV effects of canagliflozin observed in the
 CREDENCE trial could have a substantial impact on improv-
ing outcomes for patients with T2DM and CKD.
Introduction
Burden and Mechanisms of Chronic Kidney Disease
Chronic kidney disease (CKD) is defined by the Kid-
ney Disease: Improving Global Outcomes working group 
as abnormalities of kidney structure or function present 
for > 3 months, with implications for health. The Kidney 
Disease: Improving Global Outcomes CKD risk score is 
classified based on estimated glomerular filtration rate 
(eGFR) and albuminuria [1]. The prevalence of CKD has 
been estimated to be between 10 and 13% globally and 
14.8% in the United States and is expected to increase due 
to the aging global population and rising prevalence of 
diabetes and hypertension [2, 3]. 
CKD affects approximately 40% of patients with type 2 
diabetes mellitus (T2DM), and diabetes is the leading 
cause of CKD [3]. It is recommended that all patients 
with T2DM have urinary albumin-creatinine ratio 
(UACR) and eGFR screenings annually because 
 progression to substantial proteinuria (protein excretion 
> 300 mg/g) is a strong predictor of rapid progression of
CKD to end-stage kidney disease (ESKD). Despite this,
CKD awareness among health care providers is low,
which can be a barrier to providing effective care; in the
United States, 48% of those with severely reduced kidney 
function who are not on dialysis are unaware that they
have CKD [4, 5].
Unlike cardiovascular (CV) disease, for which many 
cardioprotective medications are available, physicians 
have limited treatment options beyond glycemic control 
and antihypertensive therapy to slow CKD progression. 
There have been no new treatments in 18 years, since the 
development of renin-angiotensin-aldosterone system 
(RAAS) inhibitors, including angiotensin-converting 
 enzyme (ACE) inhibitors and angiotensin receptor 
 blockers (ARBs), leaving a substantial residual risk for 
 renal failure to occur [6, 7]. 
Several key potentially modifiable factors, including 
obesity, hyperglycemia, and systemic hypertension, may 
work together to drive maladaptive processes, such as in-
sulin resistance, glomerular hyperfiltration, inflamma-
tion, proteinuria, and CV disease, that contribute to the 
development and progression of CKD in patients with 
T2DM. Additionally, patients with CKD are at an in-
creased risk for several safety concerns as a result of their 
progressive renal insufficiency, including hypoglycemia, 
hyperlipidemia, hypertension, hyperkalemia, hyperphos-
phatemia, hyperuricemia, anemia, fluid retention and 
heart failure, metabolic bone disease, amputation, and al-
tered drug clearance [8–13]. 
Current Treatment Options for Patients with T2DM 
and CKD
Treatment for patients with T2DM and CKD aimed 
at reducing the rate of progression to ESKD is limited to 
management of underlying risk factors, including hyper-
tension, dyslipidemia, and hyperglycemia, and limiting 
dietary protein intake [14–16]. In patients with hyper-
tension, reducing blood pressure (BP) to < 140/90 mm Hg 
is recommended to slow CKD progression, though a tar-
get of < 130/80 mm Hg may be appropriate for some pa-
tients, and treatment with an ACE inhibitor or ARB is 
recommended [16]. At least annual screening of creati-
nine, eGFR, and UACR is recommended for patients 
with T2DM, and monitoring of electrolytes, eGFR, and 
UACR should be more frequent after a diagnosis of CKD 
[16].
The current treatment paradigm for managing renal 
outcomes in patients with T2DM and CKD is largely 
based on results from 2 landmark trials of ARBs: Reduc-
tion of Endpoints in NIDDM with the Angiotensin II 
 Antagonist Losartan Study (RENAAL) and Irbesartan 
Diabetic  Nephropathy Trial (IDNT) [6, 7]. In RENAAL, 
treatment with losartan was associated with a 16% reduc-
tion in the risk of the composite outcome of doubling of 
serum creatinine, ESKD, or death compared with placebo 
in patients with T2DM and nephropathy [6]. In IDNT, 
treatment with irbesartan reduced the risk of a composite 
outcome of doubling of serum creatinine, ESKD, or death 
with irbesartan by 20% compared with placebo and by 
23% compared with amlodipine (a calcium channel 
blocker) in patients with hypertension, T2DM, and pro-
teinuria [7]. 
Though RAAS inhibitors can ameliorate hyperten-
sion and hyperfiltration, only 3 agents are indicated for 
the treatment of nephropathy in patients with diabetes 
(i.e., captopril for type 1 diabetes mellitus [T1DM]; losar-
tan and irbesartan for T2DM) [17–19]. Consistent effects 
on ESKD endpoints are not observed across all RAAS 
inhibitors, and these agents are not thought to affect hy-
perglycemia or obesity and do not reduce the risk of CV 
outcomes, independent of BP control [20]. However, not 
all agents have been studied, and there may be differ-
ences based on dose. Furthermore, increased risk of hy-
perkalemia and changes in serum creatinine are viewed 
as safety concerns by clinicians [21]. Additionally, de-
spite a 22% reduction in the risk of doubling of serum 
creatinine or renal replacement therapy, meta-analytic 
results suggest that as a class, RAAS inhibitors do not 
significantly reduce the risk of ESKD [22, 23]. However, 
these observations need to be tempered because not all 
studies were adequately powered to examine this end-
point.
One observational study of patients with T2DM and 
stages 3/4 CKD showed that 84% are being treated with 
RAAS inhibitors and only 26% are being treated with 
the maximum dose [24]. Thus, either undertreatment or 
the inability to tolerate the maximum dose of a RAAS 
inhibitor may contribute to higher risk of CKD progres-
sion in people with T2DM and CKD, especially as the 
severity of CKD worsens [25]. In addition, even when 
patients are treated with the maximum dose of a RAAS 
inhibitor, there is still a high residual risk of progression 
of CKD [20]. In light of these observations, new treat-
ments are needed that can slow CKD progression, stud-
ied in properly designed trials of patients with CKD 
[26].
Renal effects of sodium glucose co-transporter 2 (SGLT2) 
inhibitors were suggested in CV outcomes trials (CVOTs) 
of patients with T2DM and high CV risk [27–29]. The 
Canagliflozin and Renal Events in Diabetes with  Established 
Nephropathy Clinical Evaluation  (CREDENCE) trial of 
canagliflozin has provided the first definitive evidence of 
renal protection with an SGLT2 inhibitor in patients with 
T2DM and CKD. This article reviews the evidence for the 
effects of SGLT2 inhibitors on renal outcomes, with a focus 
on the results from CREDENCE and the implications for 
clinical practice.
Defining Renal Endpoints in Patients with CKD
Due to variability in CKD progression, it can be chal-
lenging to measure the impact of new therapies on renal 
outcomes, even in high-risk populations [30]. In addition 
to hard renal outcomes like ESKD and renal death, sur-
rogate endpoints like the doubling of serum creatinine 
(roughly equivalent to a 57% reduction in eGFR) and 
 albuminuria have been used in clinical trials of patients 
with CKD. However, there may be some limitations 
 associated with these endpoints because accumulating a 
reasonable number of these events requires large num-
bers of patients and long follow-up duration, and  changes 
in surrogate endpoints do not always correlate with hard 
renal outcomes [30–35]. Additionally, albuminuria alone 
is not considered a surrogate endpoint because it does not 
predict the endpoint of interest and is subject to high 
 levels of variance [36, 37]. Although there is ongoing 
work on identifying novel renal endpoints to predict pro-
gression to ESKD [38], clinically meaningful renal out-
comes, such as ESKD, remain important to definitively 
demonstrate renal benefits in patients with T2DM and 
CKD [39].
Supporting Renal Evidence from Large Outcomes 
Trials of SGLT2 Inhibitors
The CVOTs of SGLT2 inhibitors (Empagliflozin, 
 Cardiovascular Outcomes, and Mortality in Type 2 
 Diabetes [EMPA-REG OUTCOME] trial of empagliflozin, 
 CANagliflozin cardioVascular Assessment Study 
 [CANVAS] Program trials of canagliflozin, and Dapa-
gliflozin Effect on Cardiovascular Events  [DECLARE] 
 trial of dapagliflozin) were designed to evaluate CV safety 
for the endpoints of nonfatal myocardial infarction, non-
fatal ischemic stroke, and CV death in patients with T2DM 
and either prevalent CV disease or high risk for CV events. 
Though the populations in these studies did not have high 
proportions of patients with CKD (< 26% of patients had 
eGFR < 60 mL/min/1.73 m2 and < 12% of patients had 
UACR > 300 mg/g) and were not powered for renal out-
comes, positive effects on renal outcomes were demon-
strated in EMPA-REG OUTCOME [28], the CANVAS 
Program [27], and DECLARE [29]. 
While participants had low renal risk, these results sug-
gested that SGLT2 inhibitors may provide reductions in 
the risk of renal composite endpoints compared with pla-
cebo (Table 1). Variation in baseline renal function and the 
endpoints selected are likely largely responsible for the dif-
ferences in renal outcomes among these  CVOTs [40]. Fur-
thermore, renal endpoints in these trials were exploratory.
The effects of dapagliflozin were also studied in the 
Dapagliflozin and Prevention of Adverse Outcomes in 
Heart Failure (DAPA-HF) trial of patients with heart fail-
ure and reduced ejection fraction, which included those 
with and without diabetes. A higher proportion of pa-
tients in DAPA-HF had renal impairment (41% had 
eGFR < 60 mL/min/1.73 m2) compared with the  CVOTs, 
and dapagliflozin showed a positive effect on the renal 
outcome of ≥50% eGFR reduction, ESKD, or renal death 
(hazard ratio [HR] 0.71, 95% CI 0.44–1.16) [41].
Renal Outcomes with Canagliflozin in Patients with 
T2DM and CKD in the CREDENCE Trial
The CREDENCE trial was the first dedicated renal 
outcomes trial of an SGLT2 inhibitor designed for 
 patients with T2DM and CKD who were receiving clini-
cally appropriate RAAS inhibition and powered for renal 
endpoints [42]. The CREDENCE trial, which was con-
ceived in 2012 and enrolled its first patient in early 2014 
prior to data availability from any CVOTs, provided the 
first efficacy and safety data for a population with T2DM 
and CKD that was not selected based on their CV risk.
CREDENCE enrolled patients ≥30 years of age with 
T2DM, glycated hemoglobin A1c (HbA1c) ≥6.5–≤10.5%, 







Doubling of serum creatinine†,
ESKD, or renal death
6.3 vs. 11.5 per 1,000 PY
HR 0.54 (p < 0.001)
1.5 vs. 2.8 per 1,000 PY
HR 0.53 (95% CI 0.33–0.84)
Doubling of serum creatinine,
ESKD, or renal or CV death
13.2 vs. 15.8 per 1,000 PY
HR 0.82 (95% CI 0.68–0.97)
Doubling of serum creatinine†,
ESKD, renal death, or
new-onset macroalbuminuria
47.8 vs. 76.0 per 1,000 PY
HR 0.61 (p < 0.001)
15.1 vs. 27.4 per 1,000 PY
HR 0.58 (95% CI 0.50–0.67)
Doubling of serum creatinine†,
ESKD, renal death, new-onset
macroalbuminuria, or CV death
60.7 vs. 95.9 per 1,000 PY
HR 0.61 (p < 0.001)
40% eGFR reduction‡, ESKD,
or renal death
5.5 vs. 9.0 per 1,000 PY
HR 0.60 (95% CI 0.47–0.77)
3.7 vs. 7.0 per 1,000 PY
HR 0.53 (95% CI 0.43–0.66)
40% eGFR reduction‡, renal death,
ESKD, or renal or CV death
16.9 vs. 21.6 per 1,000 PY
HR 0.77 (95% CI 0.66–0.89)
10.8 vs. 14.1 per 1,000 PY
HR 0.76 (95% CI 0.67–0.87)
40% eGFR reduction, ESKD,
renal death or development of
macroalbuminuria
18.6 vs. 33.3 per 1,000 PY
HR 0.57 (95% CI 0.50–0.66)
Doubling of serum creatinine† 5.5 vs. 9.7 per 1,000 PY
HR 0.56 (p < 0.001)
1.2 vs. 2.4 per 1,000 PY
HR 0.50 (95% CI 0.30–0.84)
40% eGFR reduction 5.3 vs. 8.7 per 1,000 PY
HR 0.60 (95% CI 0.47–0.78)
ESKD 1.0 vs. 2.1 per 1,000 PY
HR 0.45 (p = 0.04)
0.4 vs. 0.6 per 1,000 PY
HR 0.77 (95% CI 0.30–1.97)
ESKD or renal death 0.4 vs. 0.8 per 1,000 PY
HR 0.56 (95% CI 0.23–1.32)
New-onset albuminuria 252.5 vs. 266.0 per 1,000 PY
HR 0.95 (ns)
100.4 vs. 130.8 per 1,000 PY
HR 0.80 (95% CI 0.73–0.88)
New-onset microalbuminuria 96.7 vs. 127.3 per 1,000 PY
HR 0.80 (95% CI 0.73–0.87)
New-onset macroalbuminuria§ 41.8 vs. 64.9 per 1,000 PY
HR 0.62 (p < 0.001)
15.1 vs. 27.6 per 1,000 PY
HR 0.58 (95% CI 0.50–0.68)
Progression of albuminuria 89.4 vs. 128.7 per 1,000 PY
HR 0.73 (95% CI 0.67–0.79)
* While prespecified, the renal outcomes reported for the CANVAS Program are outside the formal hypothesis testing sequence;
therefore, no p values are reported.
† With eGFR ≤45 mL/min/1.73 m2 in EMPA-REG OUTCOME.
‡ With eGFR <60 mL/min/1.73 m2 in DECLARE.
§ UACR >300 mg/g with a UACR in EMPA-REG OUTCOME.
CVOT, cardiovascular outcomes trial; SGLT2, sodium glucose co-transporter 2; EMPA-REG OUTCOME, Empagliflozin, Cardio-
vascular Outcomes, and Mortality in Type 2 Diabetes; CANVAS, CANagliflozin cardioVascular Assessment Study; DECLARE, Dapag-
liflozin Effect on Cardiovascular Events; ESKD, end-stage kidney disease; PY, patient-years; HR, hazard ratio; CV, cardiovascular; eGFR, 
estimated glomerular filtration rate; ns, not significant; UACR, urinary albumin-creatinine ratio.
and CKD (defined as eGFR 30–< 90 mL/min/1.73 m2 and 
albuminuria [UACR > 300–5,000 mg/g]) [43]. Patients 
were required to be on an ACE inhibitor or ARB for 
≥4 weeks prior to randomization at either the maximum 
labeled or tolerated dose. A total of 4,401 patients were 
randomized to canagliflozin 100 mg or placebo. At base-
line, patients had a mean age of 63 years, HbA1c of 8.3%, 
eGFR of 56.2 mL/min/1.73 m2, and median UACR of 
927.0 mg/g. About half (50.4%) of patients had a history 
of CV disease and 14.8% had a history of heart failure.
The primary outcome of CREDENCE was the compos-
ite of doubling of serum creatinine, ESKD (requirement 
for renal replacement therapy in the form of chronic di-
alysis  or transplantation or sustained eGFR < 15 mL/
min/1.73  m2), and renal or CV death. Canagliflozin treat-
ment was associated with a 30% lower relative risk of the 
primary outcome compared with placebo (HR 0.70, 95% 
CI 0.59–0.82; p = 0.00001; Fig. 1a), with all components of 
the composite contributing to the outcome [43]. Consis-
tent effects on the primary outcome were observed 
across  prespecified subgroups including by screening 
eGFR (30–< 45, 45–< 60, and 60–< 90 mL/min/1.73 m2) 
and baseline UACR (≤1,000 or > 1,000 mg/g) at baseline, 
independent of effects on HbA1c. In exploratory analyses 
of the components of the primary outcome, canagliflozin 
treatment was associated with a 32% reduction in ESKD 
(HR 0.68, 95% CI 0.54–0.86; p = 0.002) and a reduction in 
dialysis, kidney transplantation, or renal death (HR 0.72, 
95% CI 0.54–0.97). Canagliflozin reduced the risk of the 
secondary renal composite outcome of doubling of serum 
creatinine, ESKD, or renal death (HR 0.66, 95% CI 0.53–
0.81; p < 0.001; Fig. 1b) [43]. In addition to the effects on 
renal outcomes, canagliflozin was also associated with re-
ductions in the CV composite outcomes of CV death or 
hospitalization for heart failure (HR 0.69, 95% CI 0.57–
0.83; p < 0.001); CV death, myocardial infarction, or stroke 
(HR 0.80, 95% CI 0.67–0.95; p = 0.01); and hospitalization 
for heart failure (HR 0.61, 95% CI 0.47–0.80; p < 0.001; 
Fig. 1b) [43]. In the overall population, the number needed 
to treat for 2.5 years to prevent 1 event was 22 for the pri-
mary composite outcome; 28 for the ESKD, doubling of 
serum creatinine, or renal death; 43 for ESKD; 46 for hos-
pitalization for heart failure; 29 for CV death or hospital-
ization for heart failure; and 40  for CV death, nonfatal 
myocardial infarction, and nonfatal stroke [43, 44]. The 
effects of canagliflozin on renal and CV outcomes, includ-
ing the primary renal outcome and the composite of CV 
death, myocardial infarction, or stroke, were consistent in 
subgroups of participants with and without prior CV dis-
ease (Fig. 1b); canagliflozin was the first treatment to show 
a benefit for the composite of nonfatal myocardial infarc-
tion, nonfatal stroke, or CV death in primary prevention 
patients with T2DM and CKD [44]. The effects of cana-
gliflozin on renal and CV outcomes were also consistent 
in subgroups by screening eGFR (30– < 45, 45–< 60, and 
60–< 90 mL/min/1.73 m2; all  p  for heterogeneity ≥0.11; 
Fig.  1c)  [45]. Although  CREDENCE participants had 
eGFR 30– < 90 mL/min/1.73 m2 at screening, 174 patients 
had eGFR < 30 mL/min/1.73 m2 at baseline; the effects of 
canagliflozin on renal and mortality outcomes in these 






































HR 0.70 (95% CI 0.59–0.82)
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Fig. 1. Effects of canagliflozin on (a) the 
primary composite outcome of ESKD, 
doubling of serum creatinine, or renal or 
CV death in the overall CREDENCE popu-
lation [43], (b) renal, CV, and mortality 
outcomes in primary and secondary pre-
vention cohorts [44], and (c) renal, CV, 
and mortality outcomes in subgroups de-
fined by screening eGFR [45]. a From 
Perkovic et al. [43]. Copyright © 2019 Mas-
sachusetts Medical Society. Reprinted with 
permission from Massachusetts Medical 
Society. b Reprinted with permission from 
 Mahaffey et al. [44]. *  Exploratory out-
come. ESKD, end-stage kidney disease; 
CV, cardiovascular; CREDENCE, Cana-
gliflozin and Renal Events in Diabetes with 
Established Nephropathy Clinical Evalua-
tion; eGFR, estimated glomerular filtration 















(Figure continued on next pages.)
As expected, due to the acute hemodynamic effects of 
SGLT2 inhibition, there was a greater reduction in eGFR 
with canagliflozin than placebo over the first 3 weeks of 
treatment (between-group difference, –3.17 mL/min/ 
1.73 m2; Fig. 2) [43]. However, after the first 3 weeks, pa-
tients treated with canagliflozin had an approximately 60% 
slower annual rate of eGFR decline than with placebo (–1.85 
vs. –4.59 mL/min/1.73 m2, respectively; between-group dif-
ference, 2.74 mL/min/1.73 m2), suggesting that canagliflozin 
changes renal hemodynamics [43]. Off-treatment effects on 
eGFR were not tested in CREDENCE, but reversible acute 
effects of SGLT2 inhibitors on eGFR were demonstrated in 
EMPA-REG OUTCOME and CANVAS-R [27, 28]. 
Patients with later stages of CKD and T2DM have frag-
ile health and are at high risk of renal and nonrenal com-
plications [47], so higher rates of adverse events would be 
expected in CREDENCE compared with other clinical 
trials of SGLT2 inhibitors. The safety profile of cana-
gliflozin in CREDENCE was generally similar to previous 
studies of canagliflozin. Overall, there were  fewer adverse 
events (HR 0.87, 95% CI 0.82–0.93) and serious adverse 
events (HR 0.87, 95% CI 0.79–0.97) with canagliflozin 
0.91
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1
versus placebo [43]. The risk of renal- related adverse 
events was lower with canagliflozin  versus placebo 
(HR 0.71, 95% CI 0.61–0.82) and there was no difference 
in the risk of acute kidney injury (HR 0.85, 95% CI 0.64–
1.13). The risk of diabetic ketoacidosis was low in both 
groups, but higher with canagliflozin than placebo (2.2 vs. 
0.2 events per 1,000 patient-years, respectively; HR 10.80, 
95% CI 1.39–83.65); 11 of the 12 participants with dia-
betic ketoacidosis events were on insulin [43]. Consistent 
with previous studies, including the CANVAS Program, 
an increased risk of genital mycotic infections was seen 
with canagliflozin compared with placebo (males: 
HR 9.30, 95% CI 2.83–30.60; females: HR 2.10, 95% CI 
1.00–4.45). There were no differences in risks of hyperka-
lemia, hypoglycemia, osmotic diuresis, or volume deple-
tion events with canagliflozin versus placebo. 
Increased risk of amputation and fracture were identi-
fied as safety signals in the CANVAS Program CVOT of 
canagliflozin [27]. The separation in amputation event 
rates between canagliflozin and placebo became apparent 
at ∼6 months after randomization, but no specific cause,
mechanism, or at-risk subgroup for increased amputa-
tion risk has been identified despite extensive post hoc 
analyses [48]. When the increased risk of amputation was 
identified in the CANVAS Program, a protocol amend-
ment was introduced in CREDENCE that asked investi-
gators to examine patients’ feet at each trial visit, in 
 accordance with good clinical practice, and to  temporarily 
interrupt the assigned treatment in patients with any 
 active condition that might lead to amputation [43]. 
 CREDENCE participants had a higher baseline risk and 
rate of amputation than those in the CANVAS Program 
(5.3 vs. 2.3% with prior amputation at baseline, respec-
tively) [27, 43]. Consistent with the higher risk of ampu-
tation at baseline, placebo-treated participants had high-
er rates of amputation in CREDENCE than the CANVAS 
ESKD, doubling of serum creatinine, or renal or CV death
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Program (11.2 and 3.4 events per 1,000 patient-years, re-
spectively) [27, 43]. However, no difference in the risk of 
amputation was observed comparing canagliflozin- to 
placebo-treated patients in CREDENCE (12.3 vs. 11.2 
events per 1,000 patient-years, respectively; HR 1.11, 
95% CI 0.79–1.56) over a mean follow-up time of 2.6 years 
[27, 43]. In the CANVAS Program, an increased risk of 
fracture was seen in the CANVAS study, but not in 
 CANVAS-R [27]. There was no difference in the risk of 
adjudicated fracture with canagliflozin versus placebo 
(11.8 vs. 12.1 events per 1,000 patient-years, respectively; 
HR 0.98, 95% CI 0.70–1.37) [43], consistent with all but 
1 trial of canagliflozin (the CANVAS study). Despite ex-
tensive post hoc analyses, no specific cause to explain this 
discrepancy has been identified, though an unidentified 
fall-related mechanism remains a possibility [49].
Clinical Perspective
The lack of new treatments for and increased preva-
lence of CKD over the last 2 decades has presented a chal-
lenge for both patients and physicians. The emergence of 
positive renal results from CREDENCE suggests that 
canagliflozin may have the therapeutic potential to sub-
stantially improve outcomes for people with T2DM and 
CKD on top of standard-of-care treatment with an ACE 
inhibitor or ARB. In real-world clinical practice, 5% of 
patients with T2DM would meet eligibility criteria for 
CREDENCE (∼2 million US adults; Fig.  3) [50, 51].
 Although CVOTs provided some evidence of external 
 validity in terms of renoprotection with SGLT2 inhibi-
tors, CVOT participants had substantially better renal 
function than those in CREDENCE (Fig.  3); therefore, 
dedicated trials examining the risk of renal failure and 
death in patients with T2DM and CKD were needed to 
provide definitive evidence for the effects of SGLT2 
 inhibitors on renal outcomes and safety [40]. 
CREDENCE demonstrated that in patients with T2DM 
and CKD, treatment with canagliflozin significantly 
 reduced the risk of doubling of serum creatinine, ESKD, 
or renal or CV death compared with placebo. Cana-
gliflozin also reduced the risk of ESKD alone and CV end-
points, including the composite of CV death, myocardial 
infarction, or stroke and hospitalization for heart failure, 
 suggesting that canagliflozin may provide both renal and 
CV protection for patients with T2DM and CKD, with 
and without prior atherosclerotic CV disease. As a result, 
the FDA has recently approved canagliflozin for reducing 
the risk of ESKD, doubling of serum creatinine, CV death, 
and hospitalization for heart failure in adults with T2DM 
and diabetic nephropathy with albuminuria [52]. 
CREDENCE provided the first-ever safety data of 
an SGLT2 inhibitor in patients with T2DM and CKD. Re-
assuringly, the overall safety profile of canagliflozin 
in   CREDENCE was consistent with known adverse 
events, with no increased risk of hypoglycemia or acute 
kidney injury. Unlike the CANVAS Program, there were 
no imbalances between canagliflozin and placebo for am-
putation or fracture, indicating that although this popula-
tion has a higher baseline risk of these outcomes, these are 
not safety concerns with canagliflozin for the population 
studied in CREDENCE when used in the manner 
 studied – namely, good clinical practice with  respect to 
diabetic foot care and peripheral artery disease including 
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Difference: 2.74/year (95% CI 2.37–3.11)* Placebo: –4.59/year
Fig. 2. Effects on eGFR in CREDENCE. 
 Reprinted with permission from Perkovic 
et al. [43]. * Sixty percent reduction in the 
rate of eGFR decline with canagliflozin. 
eGFR, estimated glomerular filtration rate; 
CREDENCE, Canagliflozin and Renal 
Events in Diabetes with Established 
















tion within 12 months, or an active foot ulcer, osteomy-
elitis, gangrene, or critical ischemia of the lower extrem-
ity  within 6 months and interruption of therapy upon the 
emergence of any of the above with careful consideration 
of the individual risks and benefits prior to  restarting 
canagliflozin after resolution of the event.  Additionally, 
unlike studies of RAAS inhibitors, no  increase in the risk 
of hyperkalemia was seen in  CREDENCE, even on top of 
maximum-tolerated ACE inhibitor or ARB  therapy.
However, there are some limitations associated with 
the study. Although CREDENCE was stopped early for 
efficacy at a planned interim analysis for the primary end-
point, the resulting follow-up time was relatively short 
(median of 2.6 years), which may have limited the power 
for some secondary outcomes and increased the risk of 
overestimating effect size [43].
The interest in the effects of antihyperglycemic agents 
in patients with CKD has led to plans for studies with 
other agents in people with and without T2DM [53–55]. 
The ongoing DAPA-CKD and EMPA-KIDNEY studies 
of dapagliflozin and empagliflozin will provide  additional 
data on the potential for SGLT2 inhibitors to slow the 
progression of CKD in people with CKD with or without 
T2DM, and other studies will provide data on the effects 
of empagliflozin on hyperfiltration in patients with T1DM 
[53, 54, 56]. Future studies could investigate whether 
therapy with canagliflozin and other agents, such as non-
steroidal mineralocorticoid receptor agonists, which are 
currently in development, could have synergistic effects 
in the kidney and heart [57].
Several mechanisms may contribute to the renal protec-
tive effects seen with canagliflozin, including reductions in 
HbA1c, body weight, BP, and albuminuria [58–63]. The 
effects of SGLT2 inhibitors on BP and body weight are in-
dependent of urinary glucose excretion [64–66]. However, 
data from CREDENCE suggest that the effects of cana-
gliflozin on renal outcomes may be independent of effects 
on blood glucose, particularly because renoprotection is 
seen in patients with low eGFR levels who have negligible 
glucosuria [45, 67]. In addition, SGLT2 inhibitors have 
negligible long-term effects on serum potassium and an 
acute effect on serum creatinine that provides stable long-
term benefits [58, 68]. Furthermore, SGLT2 inhibition 
may confer renal protection via renal hemodynamic 
changes, such as attenuation of renal hyperfiltration and 
normalization of tubuloglomerular feedback by blocking 
sodium reabsorption at renal proximal tubules, thereby in-
creasing sodium delivery to the macula densa [62, 69–72]. 
In response, there is increased afferent arteriole tone, de-

































































Fig. 3. Proportion of patients with T2DM and CREDENCE and 
CVOT eligibility by Kidney Disease: Improving Global Out-
comes risk score. Proportion of patients with T2DM in each 
eGFR and UACR category based on US EHR data from Bailey et 
al. [50]. Position of mean eGFR and albuminuria shown for each 
trial are estimates. T2DM, type 2 diabetes mellitus; CREDENCE, 
Canagliflozin and Renal Events in Diabetes with Established 
 Nephropathy Clinical Evaluation; CVOT, cardiovascular out-
comes trial; eGFR, estimated glomerular filtration rate; UACR, 
urinary albumin-creatinine ratio; EMPA-REG OUTCOME, 
 Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 
Diabetes; CANVAS, CANagliflozin cardioVascular Assessment 















intraglomerular pressure [62, 70–72]. The renal hemody-
namic hypothesis is further supported by results of a study 
of empagliflozin in patients with T1DM [69] and by animal 
studies of empagliflozin and dapagliflozin [73, 74]. Global 
hemodynamic effects of SGLT2 inhibitors on interstitial 
fluid may also contribute to renoprotection. SGLT2 inhibi-
tion reduces interstitial fluid with minimal impact on 
blood volume and perfusion [75, 76]. Another hypothesis 
has suggested that SGLT1 senses increased glucose in the 
macula densa, which increases production of nitric oxide, 
thereby blunting tubuloglomerular feedback and promot-
ing glomerular hyperfiltration [77]. Additional putative 
renoprotective mechanisms have been postulated or 
 proposed, which include reduction of albuminuria; reduc-
tion of glucose-mediated inflammation, proliferation, and 
 fibrosis; proximal tubule hypertrophy; reduction of oxida-
tive stress; and competitive inhibition of the family of 
 sodium-hydrogen exchanger (NHE) channels in target 
 organs including the heart and kidneys [73, 74, 78–80]. In 
addition, reductions in interstitial fluid and normalization 
of endothelial dysfunction may provide renal and CV pro-
tection [66, 75, 76, 81].
SGLT2 inhibitors may also contribute to renal protec-
tion through their effects on CV disease, including in-
creases in lipolysis and ketogenesis, which change cellular 
energetics; increases in natriuresis and osmotic diuresis, 
which reduce pressure and volume overload; and off- 
target inhibition of the NHE family of channels which are 
responsible for rapid restoration of intracellular pH [40, 
82–84]; and through favorable effects via NHE1 inhibition 
in ischemia-reperfusion [85]. In the kidney, SGLT2 inhi-
bition may also inhibit NHE3 in the proximal tubule, with 
implications on natriuretic, GFR, and BP effects [86]. An-
other interesting mechanistic hypothesis is that the keto-
nemia among those treated with SGLT2 inhibitors may 
influence the relative utilization of glucose and fatty acids 
in cellular respiration that could be partially responsible 
for the observed CV and renal effects [87]. Details of these 
potential mechanisms are beyond the scope of this review.
SGLT2 inhibition may provide a more “user friendly” 
approach to kidney protection compared with RAAS 
 inhibitors because there is less of a change in eGFR and 
limited to no effect on serum potassium. Thus, clinicians 
may be more likely to use these drugs, specifically in 
 people with reduced kidney function. Based on data from 
 CREDENCE, the American Diabetes Association guide-
lines were updated in June 2019 to suggest consideration 
of use of an SGLT2 inhibitor in patients with T2DM and 
CKD with eGFR ≥30 mL/min/1.73 m2 and particularly 
those with > 300 mg/g albuminuria to reduce the risk of 
CKD progression, CV events, or both [16]. Treatment 
guidelines in Europe were recently updated to recom-
mend SGLT2 inhibitors as first-line therapy in patients 
with T2DM who are at high risk of heart failure and for 
the prevention and management of CKD in patients who 
are at a high associated risk of CV disease [88]. In 
 September 2019, the US prescribing information for cana-
gliflozin  was updated to allow initiation in people with 
eGFR ≥30 mL/min/1.73 m2 and continuation of treat-
ment in those already on canagliflozin who reach eGFR 
<  30 mL/min/1.73 m2 and albuminuria > 300 mg/day until 
initiation of dialysis or kidney transplantation [52]. These 
changes should work to broaden the population eligible 
for treatment to reduce the progression of CKD.
In conclusion, the CREDENCE trial provided evi-
dence that patients with T2DM and CKD treated with 
canagliflozin have a lower risk of kidney failure and CV 
events compared with placebo with an acceptable safety 
profile. Data from additional dedicated outcomes trials in 
patients with CKD will be important to confirm whether 
renal benefits are a class effect of SGLT2 inhibitors and 
whether benefits may extend to patients with CKD with-
out diabetes to build further evidence on the renal effi-
cacy and safety of this class of drugs.
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